← All companies
QIAGEN N.V.
QGEN - CIK 0001015820
Market cap$8.03 B
Rank#1070
SEC filings471
QIAGEN N.V. trades as QGEN and has a market capitalization of $8.03 B, making it the #1070 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.09B, up 5.7% from the prior year and net income of $424.88M. This page tracks QIAGEN N.V. through 471 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$2.09BFY 2025
Net income (latest FY)$424.88MFY 2025
Operating cash flow (latest FY)$654.33MFY 2025
Total assets (latest FY)$6.28BFY 2025
Gross margin62.2%latest FY
Net margin20.3%latest FY
Financial performance
Over the last 9 fiscal years QIAGEN N.V.'s revenue grew from $1.34B to $2.09B, a compound annual growth rate of 5.1%. Net profit margin expanded from 6.0% to 20.3% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $8.03 B
- Share price (derived)market cap / shares outstanding
- $37.02
- P/E ratio (trailing FY)
- 18.9
- EPS (diluted)FY 2025
- $1.94
- Shares outstandingas of 2025-12-31
- 0.22B
- Total equityas of 2025-12-31
- $3.78B
- Return on equity
- 11.2%
- Long-term debtas of 2025-12-31
- $1.65B
Latest filings
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-08 |
| 6-K | - | 2026-05-08 |
| 6-K | - | 2026-05-01 |
| IRANNOTICE | - | 2026-03-20 |
| 20-F | - | 2026-03-20 |
| SCHEDULE 13G/A | - | 2026-02-10 |
| SCHEDULE 13G | - | 2026-02-06 |
| 6-K | - | 2026-02-06 |
Recent press releases
- QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows2026-05-20
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface
- QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA2026-05-19
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
- QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing2026-05-07
Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow
- QIAGEN Reports Full Results for Q1 20262026-05-06
Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth
- QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
Similar companies
The largest companies sharing QIAGEN N.V.'s SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is QIAGEN N.V.'s market cap?
QIAGEN N.V. (QGEN) has a market capitalization of $8.03 B as of 2026-06-10, ranking #1070 among US-listed companies.
How much revenue does QIAGEN N.V. make?
QIAGEN N.V. reported revenue of $2.09B for fiscal year 2025, an increase of 5.7% year over year.
Is QIAGEN N.V. profitable?
Yes. QIAGEN N.V. reported net income of $424.88M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.